Articles On Imagion Biosystems (ASX:IBX)

Imagion Biosystems (ASX:IBX) has received notification from the FDA's Center for Devices and Radiological Health (CDRH) that its MagSense System and Test for staging HER2 breast cancer has qualified for and been granted designation...

At Stockhead, we tend to judge a company’s size by its market capitalisation. But a company’s enterprise value may be substantially greater – is this good or bad? In short, it depends. Using a base of $500 million, Stockhead has recapped s...

The MagSense test aims to eliminate the unnecessary surgeries and concomitant morbidity resulting from the standard of care biopsy procedure.

Medical tech company Imagion Biosystems (ASX: IBX) has scored a key breakthrough in the development of its breast cancer-detection treatment. The company’s MagSense technology is an upgrade on existing diagnostic imaging uses tiny nanoparti...

Imagion Biosystems (ASX: IBX) has received notification from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) that the MagSense System and Test for staging HER2 breast cancer had qualified for...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Want to know when shares are coming out of escrow? We’ve been keeping tabs, so you don’t have to. Every two weeks, Stockhead takes a look at the small cap companies that are releasing shares that have been locked away in escrow. Escrow refe...